This website uses cookies to improve the functionality and performance of the website, to better understand how you use AAPA’s website and services, and to provide you with a customized experience. By continuing your use of this website, you consent to this use of cookies. See our Privacy Policy for more information.

Before the Movements Start: Spotting Risk Factors for Tardive Dyskinesia

In this video, PA Williams discusses Tardive Dyskinesia (TD), a movement disorder induced by dopamine-receptor blocking agents that impacts approximately 800,000 individuals in the United States, with 60% remaining undiagnosed. It highlights key risk factors, including age, sex, and underlying mental health conditions, while stressing the importance of early detection and education. The video aims to empower physician associates to recognize these risks and take proactive steps in patient care, emphasizing that while TD is treatable, monitoring is crucial.

Key Takeaways:

  1. Tardive Dyskinesia is a movement disorder induced by dopamine-receptor blocking agents that affects approximately 800,000 Americans.
  2. It occurs at a higher rate with first generation antipsychotics, but also occurs with second generation.
  3. It can have a significant impact on patient quality of life, but it is treatable.

Previous Series Next Video

Speaker

Click on the photo below to learn more about the speaker.

Kevin Williams, MS, MPAS, PA-C

References and Additional Resources:

Carbon M, Hsieh CH, Kane JM, Correll CU. Tardive dyskinesia prevalence in the period of second-generation antipsychotic use: A meta-analysis. J Clin Psychiatry. 2017;78(3):e264-e278. doi:10.4088/JCP.16r10832

Caroff SN. A new era in the diagnosis and treatment of tardive dyskinesia. CNS Spectr. 2023;28(4):401-415. doi:10.1017/S1092852922000992

Dhir A, Schilling T, Abler V, Potluri R, Carroll B. Estimation of Tardive Dyskinesia Incidence and Prevalence in the United States [abstract]. Mov Disord. 2017;32(suppl 2). Accessed August 5, 2025. https://www.mdsabstracts.org/abstract/estimation-of-tardive-dyskinesia-incidence-and-prevalence-in-the-united-states/

Griffiths K, Won Y, Lee Z, Wang L, Correll CU, Patel R. Identifying the diagnostic gap of tardive dyskinesia: an analysis of semi-structured electronic health record data. BMC Psychiatry. 2025;25(1):407. doi:10.1186/s12888-025-06780-w

Kuntz L. Tardive Dyskinesia in US Antipsychotic Users. Psychiatric Times. Published May 6, 2024. Accessed August 5, 2025. https://www.psychiatrictimes.com/view/tardive-dyskinesia-in-us-antipsychotic-users

Neurocrine Biosciences. Tardive Dyskinesia (TD) Overview. Published online April 2022. Accessed August 5, 2025. https://www.nami.org/NAMI/media/connect-nami/TD-Fact-Sheet.pdf

Neurocrine Biosciences Announces New Survey Revealing Need for Routine Screening and Earlier Diagnosis for People Living with Tardive Dyskinesia. Neurocrine Biosciences. Accessed August 5, 2025. https://neurocrine.gcs-web.com/news-releases/news-release-details/neurocrine-biosciences-announces-new-survey-revealing-need

Ricciardi L, Pringsheim T, Barnes TRE, et al. Treatment recommendations for tardive dyskinesia. Can J Psychiatry. 2019;64(6):388-399. doi:10.1177/0706743719828968

Robert L. Tardive Dyskinesia Facts and Figures. Psychiatric Times. May 30, 2019. Accessed August 5, 2025. https://www.psychiatrictimes.com/view/tardive-dyskinesia-facts-and-figures

Solmi M, Pigato G, Kane JM, Correll CU. Clinical risk factors for the development of tardive dyskinesia. J Neurol Sci. 2018;389:21-27. doi:10.1016/j.jns.2018.02.012

Supported by